We analyzed 1302 BC samples of all subtypes as well as a cohort of 205 TNBC samples using RB knockout (RBKO), RB-loss, E2F1-3 and E2F4KO signatures, and cyclin D1, cyclin E1 and MYC expression, as described [32–34] (Fig. 1B, C, Supplementary Fig. S2A–C). This evidence concerns the gene CCND1 and breast cancer.